DOCSLIB.ORG

Novel 9Q34.11 Gene Deletions Encompassing Combinations of Four Mendelian Disease Genes: STXBP1, SPTAN1, ENG, and TOR1A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Novel 9Q34.11 Gene Deletions Encompassing Combinations of Four Mendelian Disease Genes: STXBP1, SPTAN1, ENG, and TOR1A ORIGINAL RESEARCH ARTICLE ©American College of Medical Genetics and Genomics Novel 9q34.11 gene deletions encompassing combinations of four Mendelian disease genes: STXBP1, SPTAN1, ENG, and TOR1A Ian M. Campbell, BS1, Svetlana A. Yatsenko, MD1,14, Patricia Hixson, PhD1, Tyler Reimschisel, MD2, Matthew Thomas, MS3, William Wilson, MD3, Usha Dayal, MD4, James W. Wheless, MD5, Amy Crunk, MS6, Cynthia Curry, MD7, Nicole Parkinson, MS8, Leona Fishman, MD8, James J. Riviello, MD9, Malgorzata J.M. Nowaczyk, MD10, Susan Zeesman, MS10, Jill A. Rosenfeld, MS11, Bassem A. Bejjani, MD11, Lisa G. Shaffer, PhD11, Sau Wai Cheung, PhD1, James R. Lupski, MD, PhD1,12,13, Pawel Stankiewicz, MD, PhD1 and Fernando Scaglia, MD1,13 Purpose: A number of genes in the 9q34.11 region may be haplo­ of which molecular defects lead to early­onset primary dystonia. insufficient. However, studies analyzing genotype–phenotype corre­ Ninety­four other RefSeq genes also map to the genomic intervals lations of deletions encompassing multiple dosage­sensitive genes in investigated. the region are lacking. Conclusion: STXBP1 haploinsufficiency results in progressive Methods: We mapped breakpoints of 10 patients with 9q34.11 dele­ encephalopathy characterized by intellectual disability and may tions using high­resolution 9q34­specific array comparative genomic be accompanied by epilepsy, movement disorders, and autism. We hybridization (CGH) to determine deletion size and gene content. propose that 9q34.11 genomic deletions involving ENG, TOR1A, Results: The 9q34.11 deletions range in size from 67 kb to 2.8 STXBP1, and SPTAN1 are responsible for multisystemic vascular Mb. Six patients exhibit intellectual disability and share a common dysplasia, early­onset primary dystonia, epilepsy, and intellectual deleted region including STXBP1; four manifest variable epilepsy. disability, therefore revealing cis­genetic effects leading to complex In five subjects, deletions include SPTAN1, previously associated phenotypes. with early infantile epileptic encephalopathy, infantile spasms, intel­ Genet Med 2012:14(10):868–876 lectual disability, and hypomyelination. In four patients, the dele­ tion includes endoglin (ENG), causative of hereditary hemorrhagic Key Words: cis­genetics, dystonia, early infantile epileptic encephal­ telangiectasia. Finally, in four patients, deletions involve TOR1A, opathy, hereditary hemorrhagic telangiectasia, intellectual disability INTRODUCTION natural course consists of progressive neurological dysfunction Neonatal or early infantile epileptic encephalopathies represent manifesting with concomitant cognitive and motor impairment a class of severe epileptic disorders that can be caused by abnor­ leading to severe developmental delay (DD) or intellectual dis­ mal brain development as a result of congenital brain malfor­ ability (ID). EIEE belongs to a broader class of disorders known mations or, less frequently, by inborn errors of metabolism.1 as age­dependent epileptic encephalopathies, with evolving Early infantile epileptic encephalopathy (EIEE) with a burst­ clinical phenotype and electroencephalogram characteristics as suppression pattern, also known by the eponym of Ohtahara the brain matures.3 The majority of patients with EIEE subse­ syndrome, is a rare and severe form of epileptic encephalopa­ quently develop infantile spasms (IS), or West syndrome, later thy characterized by early­onset of intractable seizures, with in childhood. In some children, the epileptic phenotype may mostly tonic spasms or, more rarely, partial seizures and a later evolve to Lennox–Gastaut syndrome by 6 years of age.4 specific pattern on electroencephalogram known as suppres­ The etiology of EIEE is heterogeneous; structural abnormali­ sion burst.2 EIEE has a neonatal or early infantile onset and the ties of the brain such as Aicardi syndrome, cortical dysgenesis, The first two authors contributed equally to this work. B.A.B. is currently unaffiliated with Signature Genomic Laboratories. 1Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA; 2Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA; 3Department of Pediatrics, University of Virginia School of Medicine, Charlottesville, Virginia, USA; 4Carolina Neurological Clinic, Charlotte, North Carolina, USA; 5Department of Pediatric Neurology, University of Tennessee Health Science Center, Memphis, Tennessee, USA; 6Shodair Hospital, Helena, Montana, USA; 7Genetic Medicine of Central California, University of California San Francisco, Fresno, California, USA; 8Department of Pediatrics, Hospital for Sick Children, Toronto, Ontario, Canada; 9Department of Neurology, New York University Langone Medical Center, New York, New York, USA; 10Department of Pathology and Molecular Medicine and Pediatrics, McMaster University, Hamilton, Ontario, Canada; 11Signature Genomic Laboratories, PerkinElmer Inc., Spokane, Washington, USA; 12Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA; 13Texas Children’s Hospital, Houston, Texas, USA. 14Present address: Obstetrics and Gynecology and Reproductive Sciences, Magee Women’s Hospital, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. Correspondence: Fernando Scaglia ([email protected]) Submitted 3 January 2012; accepted 9 May 2012; advance online publication 21 June 2012. doi:10.1038/gim.2012.65 868 Volume 14 | Number 10 | October 2012 | GENETICS in MEDICINE Novel 9q34.11 deletions | CAMPBELL et al ORIGINAL RESEARCH ARTICLE porencenphaly, and hemimegalencephaly may be accompanied Signature Genomic Laboratories (P1, P2, and P7–P10) for a by EIEE, whereas inborn errors of metabolism such as glycine diverse range of clinical indications. Four patients (P1, P2, encephalopathy and Leigh syndrome have been associated with P7, and P8) were identified by SignatureChipOS v1.1 105K other cases.2,4 More recently, studies have ascertained that EIEE oligo whole­genome array (Agilent Technologies, Santa with a burst­suppression pattern is genetically heterogeneous Clara, CA) and two patients (P9 and P10) were identified as well, with causative mutations identified in at least 12 genes by SignatureChipOS v2.0 135K oligo whole­genome array (Supplementary Table S1, online).1,5–8 In addition to the 12 (Roche NimbleGen, Madison, WI). P4 was identified by known genes, one individual with EIEE and a de novo balanced BCM CMA v7.1 105 K oligo whole­genome array (Agilent translocation disrupting the SRGAP2 gene has recently been Technologies). P6 was identified by BCM CMA v7.4 105K reported.9 oligo exon­targeted array (Agilent Technologies). P3 and Of note, two of the genes previously implicated in the etiol­ P5 were identified by BCM CMA v8.1 180K oligo exon­ ogy of EIEE, STXBP1, and SPTAN1, are both located within the targeted array (Agilent Technologies). Informed consent for same 9q34.11 genomic region. To date, only three patients with the research use of genetic material and clinical information microdeletions encompassing both STXBP1 and SPTAN1 have was obtained from the parent or guardian of each patient. been described.8,10,11 Two subjects presented with the character­ Peripheral blood samples were obtained from individuals and istic clinical features of EIEE.8,11 Although the authors of the sec­ available family members. All subjects had apparently nor­ ond study do not specifically mention SPTAN1, it and STXBP1 mal G­banded chromosome analyses. Clinical details appear are likely deleted from the chromosome of their patient pre­ in Supplementary Materials and Methods, online. senting with IS.10 De novo missense, nonsense, frameshift, and splice­site mutations, as well as genomic deletions of STXBP1 Array-CGH studies have been found in association with EIEE, suggesting STXBP1 Patients’ genomic DNA was extracted from peripheral blood haploinsufficiency as a cause of this epileptic phenotype.8,11–14 samples according to the manufacturers’ protocols. Two sepa­ However, a 4­bp deletion within STXBP1 exon 4, resulting in a rate custom, high­resolution 9q34 arrays were designed using premature stop 41 codons downstream in the sixth of 20 exons, a 60K array format (Agilent Technologies, Santa Clara, CA) has been identified in one child of Japanese ancestry who pre­ and were used on the basis of availability at time of patient sented with IS but did not exhibit the classical features consis­ ascertainment. Version 1 of the custom array had an average tent with EIEE.12 Furthermore, other publications reporting the probe spacing of ~1,250 bp per probe; version 2 had an aver­ clinical cases of patients of diverse ethnic backgrounds affected age spacing of ~250 bp per probe. Sex­matched DNA samples with epilepsy and carrying STXBP1 mutations sometimes failed from either a normal male or female individual were used as a to identify the burst­suppression pattern on electroencephalo­ hybridization reference control. DNA digestion, labeling, and gram characteristic of EIEE.10,15,16 Finally, a de novo truncating hybridization were performed according to the manufacturer’s STXBP1 mutation has been found in a 21­year­old patient with instructions (Agilent Technologies). Data were analyzed using ID and no evidence of epilepsy, expanding the clinical spectrum Agilent Genomic Workbench Software (Agilent Technologies) associated with molecular defects of STXBP1.17 and plotted using the R Statistical Computing Package (R Core Therefore, the complete range of phenotypic features caused Development
Load more

Recommended publications
  • LRRC8A Regulates Hypotonicity-Induced NLRP3 Inflammasome Activation
    bioRxiv preprint doi: https://doi.org/10.1101/2020.06.11.146225; this version posted June 12, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. LRRC8A regulates hypotonicity-induced NLRP3 inflammasome activation Jack P. Green1*,#, Tessa Swanton1*, Lucy V. Morris1, Lina Y. El-Sharkawy2, James Cook1, Shi Yu1, James Beswick2, Antony Adamson3, Neil Humphreys3,4, Richard A. Bryce2, Sally Freeman2, Catherine Lawrence1,5, David Brough1,5,# 1Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, AV Hill Building, Oxford Road, Manchester, M13 9PT, UK. 2Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Stopford Building, Oxford Road, Manchester, M13 9PT, UK. 3Genome Editing Unit Core Facility, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. 4Present address: EMBL-Rome, Epigenetics and Neurobiology Unit, Adriano Buzzati- Traverso Campus, Via Ramarini 32, 00015 Monterotondo (RM), Italy. 5Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester M13 9PT, UK. * Contributed equally # To whom correspondence should be addressed: David Brough. Tel: +44 (0)161 275 5039; Email: [email protected] Jack Green. Tel +44 (0)161 306 0502; Email: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.06.11.146225; this version posted June 12, 2020.
    [Show full text]
  • Dystonia and Chorea in Acquired Systemic Disorders
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.65.4.436 on 1 October 1998. Downloaded from 436 J Neurol Neurosurg Psychiatry 1998;65:436–445 NEUROLOGY AND MEDICINE Dystonia and chorea in acquired systemic disorders Jina L Janavs, Michael J AminoV Dystonia and chorea are uncommon abnormal Associated neurotransmitter abnormalities in- movements which can be seen in a wide array clude deficient striatal GABA-ergic function of disorders. One quarter of dystonias and and striatal cholinergic interneuron activity, essentially all choreas are symptomatic or and dopaminergic hyperactivity in the nigros- secondary, the underlying cause being an iden- triatal pathway. Dystonia has been correlated tifiable neurodegenerative disorder, hereditary with lesions of the contralateral putamen, metabolic defect, or acquired systemic medical external globus pallidus, posterior and poste- disorder. Dystonia and chorea associated with rior lateral thalamus, red nucleus, or subtha- neurodegenerative or heritable metabolic dis- lamic nucleus, or a combination of these struc- orders have been reviewed frequently.1 Here we tures. The result is decreased activity in the review the underlying pathogenesis of chorea pathways from the medial pallidus to the and dystonia in acquired general medical ventral anterior and ventrolateral thalamus, disorders (table 1), and discuss diagnostic and and from the substantia nigra reticulata to the therapeutic approaches. The most common brainstem, culminating in cortical disinhibi- aetiologies are hypoxia-ischaemia and tion. Altered sensory input from the periphery 2–4 may also produce cortical motor overactivity medications. Infections and autoimmune 8 and metabolic disorders are less frequent and dystonia in some cases. To date, the causes. Not uncommonly, a given systemic dis- changes found in striatal neurotransmitter order may induce more than one type of dyski- concentrations in dystonia include an increase nesia by more than one mechanism.
    [Show full text]
  • Childhood Epilepsy: an Update on Diagnosis and Management
    American Journal of Neuroscience Review Childhood Epilepsy: An Update on Diagnosis and Management Khaled Saad Department of Pediatrics, Faculty of Medicine, University of Assiut, Assiut 71516, Egypt Article history Abstract: Within the past few years there is a rapid expansion in our Received: 23-10-2014 understanding of epilepsy. The development of new anti-epileptic drugs and Revised: 25-11-2014 refinements to epilepsy surgery are widening the therapeutic options for Accepted: 12-01-2015 epilepsy. In addition, the classification of the epilepsies continues to evolve based on an increased understanding of the molecular genetics of the condition and this includes the recognition of possible novel epilepsy syndromes. This review considers some of these exciting developments, as well as addressing the essential features of the diagnosis, investigations, management and impact of epilepsy in childhood. Keywords: Children, Epilepsy, Seizure, Anti-Epileptic Drugs Introduction guidelines for optimal practices, rational therapy and counseling (Aylwad, 2008; Tamber and Mountz, 2012; Epilepsy is a common heterogeneous neurological Sharma, 2013). problem in children. It exerts a significant physical, psychological, economic and social toll on children and Definitions their caregivers. Fifty million people have epilepsies A seizure is defined as an excessive burst of abnormal globally; more than half of them are children. In the synchronized neuronal activity affecting small or large USA; between 25,000 and 40,000 children will have a neuronal networks that results in clinical manifestations first non-febrile seizure each year. The problem is that are sudden, transient and usually brief. Epilepsy is further compounded in developing countries as they add defined as a disorder of the brain characterized by any of about 75-80% of new cases of epilepsy (Guerrini, 2006; the following conditions: (1) At least two unprovoked (or Tamber and Mountz, 2012; Sharma, 2013).
    [Show full text]
  • The LRRC8A:C Heteromeric Channel Is a Cgamp Transporter and the Dominant
    bioRxiv preprint doi: https://doi.org/10.1101/2020.02.13.948273; this version posted February 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The LRRC8A:C Heteromeric Channel Is a cGAMP Transporter and the Dominant cGAMP Importer in Human Vasculature Cells Lauren J. Lahey1,2, Xianlan Wen3, Rachel E. Mardjuki2,4, Volker Böhnert2,5, Christopher Ritchie2,5, Jacqueline A. Carozza2,4, Gaelen T. Hess2,6, Merritt Maduke3, Michael C. Bassik2,6, and Lingyin Li2,5,7,* 1Biophysics Program, 2Stanford ChEM-H, 3Department of Molecular and Cellular Physiology, 4Department of Chemistry, 5Department of Biochemistry, 6Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305 USA. 7Lead Contact *Correspondence: [email protected] bioRxiv preprint doi: https://doi.org/10.1101/2020.02.13.948273; this version posted February 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. SUMMARY Extracellular 2'3'-cyclic-GMP-AMP (cGAMP) is an immunotransmitter secreted by cancer cells and taken up by host cells to activate the anti-cancer STING pathway. No cGAMP exporter has been identified, and SLC19A1, a recently identified cGAMP importer, does not account for the import actiVity in most cell types. Here, we identify the LRRC8A:C heteromeric channel, a volume-regulated anion channel (VRAC), as a cGAMP transporter. This channel mediates cGAMP import or export depending on the cGAMP chemical gradient. cGAMP influences anion influx through VRAC, indicating it is likely a direct substrate of the channel.
    [Show full text]
  • Oegtp - Epilepsy Test Requisition Lab Use Only: Patient Information
    OEGTP - EPILEPSY TEST REQUISITION LAB USE ONLY: PATIENT INFORMATION: Received date: Name: Notes: Address: Date of Birth: YY/MM/DD Sex: M F Health Card No: TEST REQUEST: See page 2 for gene list for each of the panels below Epilepsy Comprehensive panel: 167 genes Childhood Onset Epilepsy panel: 45 genes Focal Epilepsy panel: 14 genes Brain Malformation Epilepsy panel: 44 genes London Health Sciences Centre – (Molecular Genetics) London Health Sciences Centre Progressive Myoclonic Epilepsy panel: 20 genes Actionable Gene Epilepsy panel: 22 genes Early Infantile Epilepsy panel: 51 genes Single gene test: Carrier Testing/ KnownFamily Mutation SAMPLE COLLECTION: Name of index case in the family (include copy of report) Date drawn: YY/MM/DD EDTA blood (lavender top) (5ml at room temp) Affected Unaffected Date of Birth: Relationship to patient: REFERRING PHYSICIAN: Authorized Signature is Required Gene: RefSeq:NM Physician Name (print): Mutation: Signature: Email: REASON FOR REFERRAL: Clinic/Hospital: Diagnostic Testing Address: Clinical Diagnosis: Telephone: Fax: CC report to: Name: Clinical Presentation: Address: Telephone: Fax: Molecular Genetics Laboratory Victoria Hospital, Room B10-123A 800 Commissioners Rd. E. London, Ontario | N6A 5W9 Pathology and Laboratory Medicine Ph: 519-685-8122 | Fax: 519-685-8279 Page 1 of 6 Page OEGTP (2021/05/28) OEGTP - EPILEPSY TEST PANELS Patient Identifier: COMPREHENSIVE EPILEPSY PANEL: 167 Genes ACTB, ACTG1, ADSL, AKT3, ALDH7A1, AMT, AP3B2, ARFGEF2, ARHGEF9, ARV1, ARX, ASAH1, ASNS, ATP1A3, ATP6V0A2, ATP7A,
    [Show full text]
  • Causes of Mortality in Early Infantile Epileptic Encephalopathy: a Systematic Review
    Epilepsy & Behavior 85 (2018) 32–36 Contents lists available at ScienceDirect Epilepsy & Behavior journal homepage: www.elsevier.com/locate/yebeh Review Causes of mortality in early infantile epileptic encephalopathy: A systematic review Graciane Radaelli a,b, Francisco de Souza Santos b, Wyllians Vendramini Borelli b,LeonardoPisanib, Magda Lahorgue Nunes b,d, Fulvio Alexandre Scorza c,d, Jaderson Costa da Costa b,d,⁎ a Federal University of São Paulo (UNIFESP)/Paulista School of Medicine, São Paulo, Brazil b Brain Institute of Rio Grande do Sul (BraIns), Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, RS, Brazil c Laboratory of Neuroscience, Department of Neurology and Neurosurgery, Federal University of São Paulo, São Paulo, SP, Brazil d CNPq, Brazil article info abstract Article history: Introduction: Early infantile epileptic encephalopathy syndrome (EIEE), also known as Ohtahara syndrome, is an Received 6 March 2018 age-dependent epileptic encephalopathy syndrome defined by clinical features and electroencephalographic Revised 25 April 2018 findings. Epileptic disorders with refractory seizures beginning in the neonatal period and/or early infancy Accepted 5 May 2018 have a potential risk of premature mortality, including sudden death. We aimed to identify the causes of death Available online xxxx in EIEE and conducted a literature survey of fatal outcomes. Methods: We performed a literature search in MEDLINE, EMBASE, and Web of Science for data from inception Keywords: “ ”“ ”“ ”“ ” “ ” Ohtahara syndrome until September 2017. The terms death sudden, unexplained death, SUDEP, lethal, and fatal and the “ ”“ ”“ ”“ Early infantile epileptic syndrome medical subject heading terms epileptic encephalopathy, mortality, death, sudden infant death syn- Suppression burst drome,” and “human” were used in the search strategy.
    [Show full text]
  • Selective Transport of Neurotransmitters and Modulators by Distinct Volume-Regulated LRRC8 Anion Channels Darius Lutter1,2,3, Florian Ullrich1,2, Jennifer C
    © 2017. Published by The Company of Biologists Ltd | Journal of Cell Science (2017) 130, 1122-1133 doi:10.1242/jcs.196253 RESEARCH ARTICLE Selective transport of neurotransmitters and modulators by distinct volume-regulated LRRC8 anion channels Darius Lutter1,2,3, Florian Ullrich1,2, Jennifer C. Lueck1,2,3, Stefan Kempa2 and Thomas J. Jentsch1,2,4,* ABSTRACT volume regulation (Jentsch, 2016; Nilius et al., 1997; Pedersen In response to swelling, mammalian cells release chloride and et al., 2016). This plasma membrane channel, which appears to be organic osmolytes through volume-regulated anion channels expressed in all cells, is normally closed but can be activated by cell swelling or other cellular signaling cascades. In most cells, VRAC (VRACs). VRACs are heteromers of LRRC8A and other LRRC8 − isoforms (LRRC8B to LRRC8E), which are co-expressed in HEK293 opening leads to an efflux of Cl , which, together with an efflux of + + and most other cells. The spectrum of VRAC substrates and its K through independent K channels, lowers the intracellular dependence on particular LRRC8 isoforms remains largely unknown. osmolarity and, by secondarily driving water efflux, results in We show that, besides the osmolytes taurine and myo-inositol, regulatory volume decrease. Cell swelling also stimulates an efflux ‘ ’ myo LRRC8 channels transport the neurotransmitters glutamate, of organic osmolytes such as -inositol, taurine and glutamate. aspartate and γ-aminobutyric acid (GABA) and the co-activator It was controversial whether this release occurs through VRAC or D-serine. HEK293 cells engineered to express defined subsets of through a distinct channel named VSOAC (for volume-sensitive LRRC8 isoforms were used to elucidate the subunit-dependence organic osmolyte/anion channel) (Jackson and Strange, 1993; of transport.
    [Show full text]
  • Neonatal Seizures Revisited
    children Review Neonatal Seizures Revisited Konrad Kaminiów 1 , Sylwia Kozak 1 and Justyna Paprocka 2,* 1 Students’ Scientific Society, Department of Pediatric Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-752 Katowice, Poland; [email protected] (K.K.); [email protected] (S.K.) 2 Department of Pediatric Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-752 Katowice, Poland * Correspondence: [email protected] Abstract: Seizures are the most common neurological disorder in newborns and are most prevalent in the neonatal period. They are mostly caused by severe disorders of the central nervous system (CNS). However, they can also be a sign of the immaturity of the infant’s brain, which is characterized by the presence of specific factors that increase excitation and reduce inhibition. The most common disorders which result in acute brain damage and can manifest as seizures in neonates include hypoxic-ischemic encephalopathy (HIE), ischemic stroke, intracranial hemorrhage, infections of the CNS as well as electrolyte and biochemical disturbances. The therapeutic management of neonates and the prognosis are different depending on the etiology of the disorders that cause seizures which can lead to death or disability. Therefore, establishing a prompt diagnosis and implementing appropriate treatment are significant, as they can limit adverse long-term effects and improve outcomes. In this review paper, we present the latest reports on the etiology, pathomechanism, clinical symptoms and guidelines for the management of neonates with acute symptomatic seizures. Keywords: neonatal seizures; pathophysiology; genetics; inborn errors of metabolism Citation: Kaminiów, K.; Kozak, S.; Paprocka, J.
    [Show full text]
  • The Dystonias
    LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES SUBJECT REVIEW The Dystonias Edith G. McGeer and Patrick L. McGeer Can. J. Neurol. Sci. 1988; 15: 447-483 Contents This review is intended for both the practitioner and the sci­ entist. Its purpose is to summarize current knowledge regarding the various forms of dystonia, as well as the pathology known Introduction to produce the syndrome in specialized circumstances. Histopathological and brain imaging studies The low incidence of the disorder, its prolonged course, and the difficulty of accurate diagnosis has precluded the type of Sleep and other physiological studies systematic investigation that is possible with many other disor­ Chemical pathology ders. Yet such systematic investigation is essential if the myster­ Brain studies ies surrounding dystonia are to be unravelled and methods of CSF studies treatment improved. Blood studies Dystonia has been defined by the Scientific Advisory Board Urine studies of the Dystonia Medical Research Foundation as a syndrome of Fibroblast studies sustained muscle contraction, frequently causing twisting and Miscellaneous repetitive movements, or abnormal posture. It is a clinical term Therapy and not a disease description. It refers to all anatomical forms, whether they involve generalized musculature or only focal Iatrogenic dystonia groups. Although dystonia appears as part of the syndrome in a Possible animal models of dystonia number of disease states, it is idiopathic dystonia, where inheri­ Summary tance is a major factor, that has aroused the greatest medical interest. This review emphasizes recent literature and those aspects which may contribute to an understanding of the under­ 1. INTRODUCTION lying mechanisms of dystonic movement.
    [Show full text]
  • Epileptic Mechanisms Shared by Alzheimer's Disease
    International Journal of Molecular Sciences Review Epileptic Mechanisms Shared by Alzheimer’s Disease: Viewed via the Unique Lens of Genetic Epilepsy Jing-Qiong Kang 1,2 1 Department of Neurology & Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232-8552, USA; [email protected]; Tel.: +1-615-936-8399; Fax: +1-615-322-5517 2 Vanderbilt Kennedy Center of Human Development, Vanderbilt Brain Institute, Vanderbilt University, Nashville, TN 37232-8522, USA Abstract: Our recent work on genetic epilepsy (GE) has identified common mechanisms between GE and neurodegenerative diseases including Alzheimer’s disease (AD). Although both disorders are seemingly unrelated and occur at opposite ends of the age spectrum, it is likely there are shared mechanisms and studies on GE could provide unique insights into AD pathogenesis. Neurodegen- erative diseases are typically late-onset disorders, but the underlying pathology may have already occurred long before the clinical symptoms emerge. Pathophysiology in the early phase of these diseases is understudied but critical for developing mechanism-based treatment. In AD, increased seizure susceptibility and silent epileptiform activity due to disrupted excitatory/inhibitory (E/I) balance has been identified much earlier than cognition deficit. Increased epileptiform activity is likely a main pathology in the early phase that directly contributes to impaired cognition. It is an enormous challenge to model the early phase of pathology with conventional AD mouse models due to the chronic disease course, let alone the complex interplay between subclinical nonconvulsive epileptiform activity, AD pathology, and cognition deficit. We have extensively studied GE, especially with gene mutations that affect the GABA pathway such as mutations in GABAA receptors and GABA transporter Citation: Kang, J.-Q.
    [Show full text]
  • Abstracts from the 51St European Society of Human Genetics Conference: Electronic Posters
    European Journal of Human Genetics (2019) 27:870–1041 https://doi.org/10.1038/s41431-019-0408-3 MEETING ABSTRACTS Abstracts from the 51st European Society of Human Genetics Conference: Electronic Posters © European Society of Human Genetics 2019 June 16–19, 2018, Fiera Milano Congressi, Milan Italy Sponsorship: Publication of this supplement was sponsored by the European Society of Human Genetics. All content was reviewed and approved by the ESHG Scientific Programme Committee, which held full responsibility for the abstract selections. Disclosure Information: In order to help readers form their own judgments of potential bias in published abstracts, authors are asked to declare any competing financial interests. Contributions of up to EUR 10 000.- (Ten thousand Euros, or equivalent value in kind) per year per company are considered "Modest". Contributions above EUR 10 000.- per year are considered "Significant". 1234567890();,: 1234567890();,: E-P01 Reproductive Genetics/Prenatal Genetics then compared this data to de novo cases where research based PO studies were completed (N=57) in NY. E-P01.01 Results: MFSIQ (66.4) for familial deletions was Parent of origin in familial 22q11.2 deletions impacts full statistically lower (p = .01) than for de novo deletions scale intelligence quotient scores (N=399, MFSIQ=76.2). MFSIQ for children with mater- nally inherited deletions (63.7) was statistically lower D. E. McGinn1,2, M. Unolt3,4, T. B. Crowley1, B. S. Emanuel1,5, (p = .03) than for paternally inherited deletions (72.0). As E. H. Zackai1,5, E. Moss1, B. Morrow6, B. Nowakowska7,J. compared with the NY cohort where the MFSIQ for Vermeesch8, A.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0210567 A1 Bevec (43) Pub
    US 2010O2.10567A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0210567 A1 Bevec (43) Pub. Date: Aug. 19, 2010 (54) USE OF ATUFTSINASATHERAPEUTIC Publication Classification AGENT (51) Int. Cl. A638/07 (2006.01) (76) Inventor: Dorian Bevec, Germering (DE) C07K 5/103 (2006.01) A6IP35/00 (2006.01) Correspondence Address: A6IPL/I6 (2006.01) WINSTEAD PC A6IP3L/20 (2006.01) i. 2O1 US (52) U.S. Cl. ........................................... 514/18: 530/330 9 (US) (57) ABSTRACT (21) Appl. No.: 12/677,311 The present invention is directed to the use of the peptide compound Thr-Lys-Pro-Arg-OH as a therapeutic agent for (22) PCT Filed: Sep. 9, 2008 the prophylaxis and/or treatment of cancer, autoimmune dis eases, fibrotic diseases, inflammatory diseases, neurodegen (86). PCT No.: PCT/EP2008/007470 erative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the S371 (c)(1), present invention relates to pharmaceutical compositions (2), (4) Date: Mar. 10, 2010 preferably inform of a lyophilisate or liquid buffersolution or artificial mother milk formulation or mother milk substitute (30) Foreign Application Priority Data containing the peptide Thr-Lys-Pro-Arg-OH optionally together with at least one pharmaceutically acceptable car Sep. 11, 2007 (EP) .................................. O7017754.8 rier, cryoprotectant, lyoprotectant, excipient and/or diluent. US 2010/0210567 A1 Aug. 19, 2010 USE OF ATUFTSNASATHERAPEUTIC ment of Hepatitis BVirus infection, diseases caused by Hepa AGENT titis B Virus infection, acute hepatitis, chronic hepatitis, full minant liver failure, liver cirrhosis, cancer associated with Hepatitis B Virus infection. 0001. The present invention is directed to the use of the Cancer, Tumors, Proliferative Diseases, Malignancies and peptide compound Thr-Lys-Pro-Arg-OH (Tuftsin) as a thera their Metastases peutic agent for the prophylaxis and/or treatment of cancer, 0008.
    [Show full text]